Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: In-vivo pharmacokinetic and toxicity study
- 1 October 2017
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 94, 150-164
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targetingEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: Physicochemical investigationsColloids and Surfaces A: Physicochemical and Engineering Aspects, 2013
- Effects of Localized Hydrophilic Mannitol and Hydrophobic Nelfinavir Administration Targeted to Olfactory Epithelium on Brain DistributionAAPS PharmSciTech, 2011
- Hematologic and Hepatic Enzyme Alterations Associated with Acute Administration of Antiretroviral DrugsJournal of Pharmacology and Toxicology, 2011
- Formulation of a Novel Oxybenzone-Loaded Nanostructured Lipid Carriers (NLCs)AAPS PharmSciTech, 2010
- Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids virusesJournal of Drug Targeting, 2009
- The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further researchAntiviral Research, 2009
- Molecular Pathology of Neuro-AIDS (CNS-HIV)International Journal of Molecular Sciences, 2009
- Physicochemical Characterization of Efavirenz–Cyclodextrin Inclusion ComplexesAAPS PharmSciTech, 2009
- Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liverBiochimica et Biophysica Acta (BBA) - General Subjects, 1979